On September 27, 2018, Decibel Therapeutics and Oricula Therapeutics announced that Decibel has obtained an exclusive, worldwide license to the development and commercialization of ORC-13661, an oral medication developed by Oricula Therapeutics for the prevention of hearing loss and balance disorders that can occur following treatment of severe infections with aminoglycoside antibiotics. Particularly susceptible populations include those treated for pulmonary exacerbations associated with cystic fibrosis, non-tuberculous mycobacterial infections, multidrug-resistant tuberculosis and endocarditis. As part of the agreement, Oricula will provide ongoing scientific advice and support.

The WilmerHale team representing Decibel in this agreement was led by Belinda Juran and included Mat Trachok and Alex Civetta.

The press release announcing the deal is available at www.decibeltx.com.